Low-dose NanoNO can not only normalize tumor blood vessels, but also significantly improved the delivery and effectiveness of chemotherapy drugs related to tumor necrosis factor, apoptosis induction, and ligand-based therapy in primary tumors and metastases (41).In addition, the Harvard team also made a breakthrough in the exploration of novel immune checkpoint targets. This evidence concerns the gene TNF and neoplasm.